SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational studyJoshua A. Hill, Miguel‐Angel Perales, Kristin Peyton et al.|EClinicalMedicine|2023Cited by 25
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational StudyJoshua A. Hill, Miguel‐Angel Perales, Michael J. Martens et al.|Clinical Infectious Diseases|2024Cited by 25
Leveraging Hematopoietic Cell Transplant Data and Biorepository Resources at the Center for International Blood and Marrow Transplant Research to Improve Patient OutcomesYung‐Tsi Bolon, Stephen R. Spellman, Rasha Atshan et al.|Transplantation and Cellular Therapy|2024Cited by 6
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101)Joshua A. Hill, Miguel‐Angel Perales, Michael J. Martens et al.|medRxiv|2024Cited by 2
Cryopreservation Changes the Immune Effector Cell Composition of Peripheral Blood Stem Cell Grafts: An Analysis from the DKMS and NMDP Graft Composition StudyElke Rücker‐Braun, Falk Heidenreich, Bose Falk et al.|Blood|2023Cited by 1